BioSpace News Archive

China Biologic today announced that its wholly-owned subsidiary Guizhou Taibang received approval from the Hainan Provincial Health and Family Planning Commission on February 13, 2018 to build a new plasma collection station in Hainan Province.

According to the terms of the agreement, PharmaMar receives an upfront payment of 5,000,000 US dollars on signing, followed by development milestones if a product enters clinical development conducted by Seattle Genetics.

The solution integrates the novel extraction chemistry on the Hamilton Microlab STAR liquid handling platform to provide high through-put solution for applications such as biorepositories, genomics research and pharmacogenomics that require substantial amounts of DNA to be extracted from large-volume samples.

Vertex Pharmaceuticals today announced positive results of a Phase 2 study of the NaV1.8 inhibitor VX-150 in patients with acute pain following bunionectomy surgery.

The Phase 3 program is the first trial in the JAK1 Atopic Dermatitis Efficacy and Safety global development program.

Novartis receives funding from Bill & Melinda Gates Foundation for further development of Novartis drug candidate KDU731 for the treatment of cryptosporidiosis.

Accordingly, this debt has now been removed from the Company’s balance sheet.

Actinic keratosis is a common skin condition that is induced through ultra-violet light damage, resulting in patches of thick, scaly, or crusty skin.

Mr. Mullennix will join the senior management team and will report to Ron Bentsur, UroGen’s CEO.

Ra Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 8,400,000 shares of its common stock at a public offering price of $6.00 per share, before underwriting discounts.